The purpose of this study is to evaluate several different tests, including brain imaging, eye movement testing, body fluid samples, measurements of memory and other thinking abilities, and measures of functional independence in the hope that this information can be used to guide diagnosis and treatment of PSP and CBD in the future. Recent advances in our understanding of the biological causes of these diseases offer hope for new treatments. As such treatments are developed, sensitive and specific biological measurements (biomarkers) will be needed to provide precise and direct measures of the state of the brain, which will improve the statistical power of clinical trials. Brain imaging with Magnetic Resonance Imaging (MRI) has previously been used to measure disease-related changes in the brain. The goal of this study is to identify the best methods of analysis (including eye movements, imaging, and behavioral measures) for tracking PSP and CBD over time. In addition, certain biomarkers in the blood and cerebrospinal fluid might also be useful for following these diseases over time. This study will examine the value of blood and CSF biomarkers relative to brain imaging and functional measures.
Study Type
OBSERVATIONAL
Enrollment
110
University of California, San Francisco
San Francisco, California, United States
John Hopkins University
Baltimore, Maryland, United States
Progressive Supranuclear Palsy Rating Scale
Change from baseline
Time frame: Baseline, 6 months and 1 year
Eye movement function
Change from baseline
Time frame: Baseline, 6 months and 1 year
Brain volume on MRI
Change from baseline.
Time frame: Baseline, 6 months and 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.